Addressing tobacco addiction in office-based management of psychiatric disorders: Practical considerations

Primary Psychiatry

Volumn 13, Issue 2, 2006, Pages 51-63

  Ziedonis, Douglas ^a,c   Williams, Jill M ^a   Steinberg, Michael ^a   Foulds, Jonathan ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CAFFEINE; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; CODEINE; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; INSULIN; NEUROLEPTIC AGENT; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NORTRIPTYLINE; OLANZAPINE; PARACETAMOL; PROPRANOLOL; THEOPHYLLINE; TRAZODONE;

ANXIETY DISORDER; BEHAVIOR THERAPY; CIGARETTE SMOKING; CLINICAL PRACTICE; COGNITIVE THERAPY; COMORBIDITY; COUGHING; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG DEPENDENCE; DRUG USE; ENVIRONMENTAL EXPOSURE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH HAZARD; HEARTBURN; HICCUP; HUMAN; INSOMNIA; INTERNET; JAW PAIN; LOZENGE; MENTAL DISEASE; MOTIVATION; MOUTH DISEASE; MOUTH IRRITATION; NAUSEA; NICOTINE REPLACEMENT THERAPY; NOSE IRRITATION; OUTPATIENT CARE; PAIN; PATIENT ASSESSMENT; PATIENT COUNSELING; PSYCHIATRIST; PSYCHOSOCIAL CARE; RASH; REVIEW; SCREENING; SKIN MANIFESTATION; SLEEP DISORDER; SMOKING CESSATION; SUBSTANCE ABUSE; TELEPHONE; THROAT IRRITATION; TOBACCO DEPENDENCE; TREATMENT PLANNING; VIVID DREAM; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 33644534450     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Practice Guideline for the Treatment of Patients with Nicotine Dependence. Washington, DC: American Psychiatric Association. 1996;153(10):1-30.
2. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177:212-217.
3. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Mental disorders and cause-specific mortality. Br J Psychiatry. 2001;179:498-502.
4. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: A population-based prevalence study. JAMA. 2000;284(20):2606-2610.
5. Center for Substance Abuse Treatment. Substance Abuse Treatment for Persons with Co-Occurring Disorders. Treatment Improvement Protocol (TIP) Series 42. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005. DHHS Publication No. (SMA) 05-3922.
6. Berger H, Schweigler M. Smoking characteristics of methadone patients. JAMA. 1972;222(6):705.
7. Richter KP, Ahluwalia JS. A case for addressing cigarette use in methadone and other opioid treatment programs. J Addict Dis. 2000;19(4):35-52.
8. Stark MJ, Campbell BK. Cigarette smoking and methadone dose levels. Am J Drug Alcohol Abuse. 1993;19(2):209-217.
9. Clarke JG, Stein MD, McGarry KA, Gogineni A, Interest in smoking cessation among injection drug users. Am J Addict. 2001;10(2):159-165.
10. Clemmey P, Brooner R, Chutuape MA, Kidorf M, Stitzer M. Smoking habits and attitudes in a methadone maintenance treatment population. Drug Alcohol Depend. 1997;44(2-3);123-132.
11. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry. 1986;143(8):993-997.
12. De Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM, Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry. 1995;152(3):453-455.
13. Ziedonis DM, Kosten TR, Glazer WM, Frances RJ. Nicotine dependence and schizophrenia. Hosp Community Psychiatry. 1994;45(3):204-206.
14. Gonzalez-Pinto A, Gutierrez M, Ezcurra J, et al. Tobacco smoking and bipolar disorder. J Clin Psychiatry. 1998;59(5):25-28.
15. Hughes JR. Combining behavioral therapy and pharmacotherapy for smoking cessation: An update. In: Oken LS, Blaine JD, Boren JJ, eds. Integrating Behavior Therapies with Medication in the Treatment of Drug Dependence. NIDA Research Monographs. Washington, DC: US Government Printing Office; 1995:92-109.
16. U.S. Department of Health and Human Services. Preventing tobacco use among young people: A report of the Surgeon General. Atlanta, Georgia: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1994. Available at: http://www.cdc.gov/tobacco/sgr/sgr_1994/index.htm. Accessed January 9, 2006.
17. Upadhyaya HP, Deas D, Brady KT, Kruesi M. Cigarette smoking and psychiatric comorbidity in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2002;41(11):1294-1305.
18. Benowitz NL. Pharmacological aspects of cigarette smoking and nicotine addiction. N Engl J Med. 1988;319(20):1318-1330.
19. Balfour DJ, Fagerstrom KO. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther. 1996;72(1):51-81.
20. Fung YK, Schmid MJ, Anderson TM, Lau YS. Effects on nicotine withdrawal on central dopaminergic systems. Pharmacol Biochem Behav. 1996;53(3):635-640.
21. Ward KD, Garvey AJ, Bliss RE, Sparrow D, Young JB, Landsberg L. Changes in urinary catecholamine excretion after smoking cessation. Pharmacol Biochem Behav. 1991;40(4):937-940.
22. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry. 2001;50(2):71-83.
23. Williams JM, Ziedonis DM. Addressing tobacco among individuals with a mental illness or an addiction. Addict Behav. 2004;29:1059-1270.
24. Ziedonis DM, George TP. Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull. 1997;23(2):247-254.
25. Williams JM, Hughes JR. Pharmacotherapy treatments for tobacco dependence among smokers with mental illness or addiction. Psychiatr Ann. 2003;33(7):457-466.
26. National Center For Chronic Disease Prevention and Health Promotion. Tobacco Information and Prevention Source (TIPS). The Health Consequences of Smoking: A Report of the U.S. Surgeon General. 2004. Available at: http://www.cdc.gov/tobacco/sgr/sgr_2004/. Accessed January 9, 2006.
27. Smoking-Attributable Mortality and Years of Potential Life Lost-United States, 1988. Atlanta, GA: Centers for Disease Control; 1991. DHHS publication CDC 91-8017. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00001886. htm. Accessed January 9, 2005.
28. Matone KM, Waternaux C, Haas GL, Cooper TB, Li S, Mann JJ. Cigarette smoking, suicidal behavior, and serotonin function in major psychiatric disorders. Am J Psychiatry. 2003;160(4);773-779.
29. Rahman M, Fukui T. Bidi smoking and health. Public Health. 2000;114(2):123-127.
30. Malson JL, Lee EM, Murty R, Moolchan ET, Pickworth WB. Clove cigarette smoking: biochemical, physiological and subjective effects. Pharmacol Biochem Behav. 2003;74(3):739-745.
31. Fisher MA, Taylor GW, Tilashalski KR. Smokeless tobacco and severe active periodontal disease, NHANES III. J Dent Res. 2005;84(8):705-710.
32. Fisher MA, Bouquot JE, Shelton BJ. Assessment of risk factors for oral leukoplakia in West Virginia. Community Dent Oral Epidemiol. 2005;33(1):45-52.
33. Thomas G, Hashibe M, Jacob BJ, et al. Risk factors for multiple oral premalignant lesions. Int J Cancer. 2003;107(2):285-291.
34. Foulds J, Ramstrom L, Burke M, Fagerstrom K. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob Control. 2003;12(4):349-359.
35. The Health Benefits of Smoking Cessation: A Report of the Surgeon General. Washington, DC: US Department of Health and Human Services; 1990.
36. Brown CA, Crombie IK, Smith WC, Tunstall-Pedoe H. The impact of quitting smoking on symptoms of chronic bronchitis: results of the Scottish Heart Health Study. Thorax. 1991;46(2):112-116.
37. Murin S, Bilello KS. Respiratory tract infections: another reason not to smoke. Cleve Clin J Med. 2005;72(10):916-920.
38. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000;321(7257):323-329.
39. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2004;(1):CD003041.
40. Adler LE, Olincy A, Waldo M, et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull. 1998;24(2):189-202.
41. George TP, Vessicchio JC, Termine A, et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology. 2002;26(1):75-85.
42. Conners CK, Levin ED, Sparrow E, et al. Nicotine and attention in adult ADHD. Psychopharmacol Bull. 1996;32(1):67-73.
43. Levin ED, Conners CK, Sparrow E, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 1996;123(1):55-63.
44. Ziedonis D, Williams JM, Smelson D. Serious mental illness and tobacco addiction: a model program to address this common but neglected issue. Am J Med Sci. 2003;326(4):223-230.
45. Stuyt EB, Order-Connors B, Ziedonis DM. Addressing tobacco through program and system change in mental health and addiction settings. Psychiatr Ann. 2003;33(7):446-456.
46. University of Medicine and Dentistry of New Jersey-School of Public Health. Tobacco Dependence Clinic. Annual Report 2004. Available at: http://www.tobaccopragram.org/. Accessed January 10, 2006.
47. American Cancer Society. Available at: www.cancer.org. Accessed January 10, 2006.
48. National Cancer Institute. Available at: www.nci.nih.gov. Accessed January 10, 2006.
49. The New York State Smokers' Quitsite. Available at www.nysmokefree.com. Accessed January 10, 2006.
50. American Lung Association. Available at: www.lungusa.org. Accessed January 10, 2006.
51. United States Department of Health and Human Services. Office of the Surgeon General. Available at: www.surgeongeneral.gov. Accessed January 10, 2006.
52. American Psychiatric Association. Available at: www.psycri.org. Accessed January 10, 2006.
53. Smokefree.gov. Available at: www.smokefree.gov. Accessed January 10, 2006.
54. Teen Quit. Available at: www.teenquit.com. Accessed January 10, 2006.
55. Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence: Quick Reference Guide for Clinicians. Rockville, MD: US Department of Health and Human Services, Public Health Service, 2000. Available at: http://www.surgeongeneral.gov/tobacco/tobaqrg.htm. Accessed January 9, 2006.
56. Fiore MC, Jorenby DE, Schensky AE, Smith SS, Bauer RR, Baker TB. Smoking status as the new vital sign: effect on assessment and intervention in the patients who smoke. Mayo Clin Proc. 1995;70(3):209-213.
57. Yen KL, Hechavarria E, Bostwick SB. Bidi cigarettes: an emerging threat to adolescent health. Arch Pediatr Adolesc Med. 2000;154(12):1187-1189.
58. Furberg H, Bulik C, Lerman C, Lichtenstein P, Pedersen NL, Sullivan PF. Is Swedish snus associated with smoking initiation or smoking cessation? Tob Control. 2005;14(6):422-424.
59. Williams JM, Ziedonis DM, Abanyie F, Steinberg ML, Foulds J, Benowitz NL. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaflective disorder is not a metabolic effect. Schizophr Res. 2005;79(2-3):323-335.
60. Jarvis MJ. A profile of tobacco smoking. Addiction. 1994;89(11):1371- 1376.
61. Sutton SR, Russell MA, Iyer R, Feyerabend C, Saloojee Y. Relationship between cigarette yields, puffing patterns, and smoke intake: evidence for tar compensation? Br Med J (Clin Res Ed). 1982;285(6342):600-603.
62. Djordjevic MV, Hoffmann D, Hoffmann I. Nicotine regulates smoking patterns. Prev Med. 1997;26(4):435-440.
63. Jarvis MJ, Tunstall-Pedoe H, Feyerabend C, Vesey C, Saloojee Y. Comparison of tests used to distinguish smokers from nonsmokers. Am J Public Health. 1987;77(11):1435-1438.
64. Grabowski J, Bell CS, eds. National Institute on Drug Abuse Research Monograph 48, Measurement in the analysis and treatment of smoking behavior. U.S. Department of Health and Human Services, 1983. Available at http://www.drugabuse.gov/pdf/monographs/48.pdf. Accessed January 9, 2006.
65. Diagnostic and Statistical Manual of Mental Disorders. 4th ed text rev. Washington, DC: America Psychiatric Association; 1994.
66. Fagerstrom Test for Nicotine Dependence. Available at: http://ww2.heartandstroke.ca/DownloadDocs/PDF/Fagerstrom_Test.pdf. Accessed January 10, 2006.
67. Heatherton TF, Kozlowski L, Frecker RC, Rickert W, Robinson J. Measuring the heaviness of smoking: using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. Br J Addict. 1989;84(7):791-799.
68. Kelly C, McCreadie RG. Smoking habits, current symptoms and premorbid characteristics of schizophrenic patients in Nitsdale, Scotland. Am J Psychiatry. 1999;156(11):1751-1757.
69. Corvin A, O'Mahony E, O'Regan M, et al. Cigarette smoking and psychotic symptoms in bipolar affective disorder. Br J Psychiatry. 2001;179:35-38.
70. Covey LS, Glassman AH, Stetner F. Depression and depressive symptoms in smoking cessation. Compr Psychiatry. 1990;31(4):350-354.
71. West RJ, Hajek P, Belcher M. Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychol Med. 1989;19(4):981-985.
72. Hughes JR. Tobacco withdrawal in self-quitters. J Consult Clin Psychol. 1992;60(5):689-697.
73. Hughes JR. Reduced smoking: an introduction and review of the evidence. Addiction. 2000;95(suppl 1):S3-S7.
74. Prochaska JO. Stages and process of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983;51(3):390-395.
75. Smoking Cessation: Quick Reference Guide for Primary Care Clinicians. Rockville, MD: Agency for Health Care Policy Reform; 1996 (AHCPR Publication No. 96-0693.)
76. Baillie AJ, Mattick RP, Hall W, Webster P. Meta-analytic review of the efficacy of smoking cessation interventions. Drug Alcohol Rev. 1994;13:157-170.
77. Haustein KO, Haffner S, Woodcock BG. A review of the pharmacological and psychopharmacological aspects of smoking and smoking cessation in psychiatric patients. Int J Clin Pharmacol Ther. 2002;40(9):404-418.
78. Sullivan MA, Covey LS. Current perspectives on smoking cessation among substance abusers. Curr Psychiatry Rep. 2002;4(5):388-396.
79. Hall SM, Reus VI, Munoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry. 1998;55(8):683-690.
80. Bobo JK, Mcllvain HE, Lando HA, Walker RD, Leed-Kelly A. Effect of smoking cessation counseling on recovery from alcoholism: findings from a randomized community intervention trial. Addiction. 1998;93(6):877-887.
81. Niaura R, Abrams DB. Stopping smoking: a hazard for people with a history of major depression? Lancet. 2001;357(9272):1900-1901.
82. Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005;25(3):218-225.
83. McFall M, Saxon AJ, Thompson CE, et al. Improving the rates of quitting smoking for veterans with post-traumatic stress disorder. Am J Psychiatry. 2005;162(7):1311-1319.
84. Milton MH, Maule CO, Yee SL, Backinger C, Malarcher AM, Husten CG. Youth Tobacco Cessation: A Guide for Making Informed Decisions. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2004. Available at: http://www.ctcri.ca/files/YTC.pdf. Accessed January 9, 2006.
85. Prochaska JO, DiClemente CC, Norcross J. In search of how people change. Applications to addictive behaviors. Am Psychol. 1992;47(9):1102-1114.
86. Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C, Golf DC. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res. 2001;3(4):397-403.
87. Weiner E, Ball MP, Summerfelt A, Gold J, Buchanan RW. Effects of sustained-release buptoprion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry. 2001;158(4):635-637.
88. Miller WR. Enhancing motivation for change. In: Miller WR, Heather N, eds. Treating Addictive Behaviors. 2nd ed. New York, NY: Plenum Press; 1998:121-132.
89. Lee EW, D'Alonzo GE. Cigarette smoking, nicotine addiction, and its pharmacologic treatment. Arch Intern Med. 1993;153(1):3448.
90. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000146.
91. West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl). 2000;149(3):198-202.
92. Gourlay S. The pros and cons of transdermal nicotine therapy. Med J Aust. 1994;160(3):152-159.
93. Working group for the study of transdermal nicotine in patients with coronary artery disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med. 1994;154(9):989-995.
94. Gross J, Stitzer ML, Maldonado J. Nicotine replacement: Effects of postcessation weight gain. J Consult Clin Psychol. 1989;57(1):87-92.
95. Fagerstrom KO, Melen B. Nicotine chewing gum in smoking cessation: Efficacy, nicotine dependence, therapy duration, clinical recommendations. In: Grabowski J, Hall SM, eds. Pharmacological Adjuncts in Smoking Cessation. Bethesda, MD: National Institute on Drug Abuse: 1985:102-109.
96. Goldstein MG, Niaura R, Follick MJ, Abrams DB. Effects of behavioral skills training and schedule of nicotine gum administration on smoking cessation. Am J Psychiatry. 1989;146(1):56-60.
97. Hajek P, Jackson P, Belcher M. Long-term use of nicotine chewing gum. Occurrence, determinants, and effect on weight gain. JAMA. 1988;260(11):1593- 1596.
98. Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med. 2002;162(11):1267-1276.
99. Sutherland G, Stapleton JA, Russell MA, et al. Randomised controlled trial of nicotine nasal spray in smoking cessation. Lancet. 1992;340(8815):324- 329.
100. Hurt RD, Wolter TD, Rigotti N, et al. Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome. Addict Behav. 2002;27(4):493-507.
101. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340(9):685-691.
102. Warner C, Shoaib M. How does bupropion work as a smoking cessation aid? Addict Biol. 2005;10(3):219-231.
103. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. 2000;295(1):321-327.
104. Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med. 1995;24(1):41-47.
105. Foulds J, Burke M, Steinberg M, Williams JM, Ziedonis DM. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs. 2004;9(1):39-53.